Oral Psoriasis Therapies
- PMID: 38796267
- DOI: 10.1016/j.det.2024.02.013
Oral Psoriasis Therapies
Abstract
Oral psoriasis therapies include both older traditional immunosuppressants, such as methotrexate, cyclosporine, and acitretin, as well as newer, more targeted agents, such as apremilast, deucravacitinib, and oral interleukin-23 receptor antagonists. Patients may prefer oral therapies to injectable therapies based on the route of administration. Both older and newer oral psoriasis therapies can be utilized effectively in the treatment of psoriasis. Here, we will review oral agents used in the treatment of psoriasis as well as provide commentary on their role in our current, evolving psoriasis treatment paradigm.
Keywords: Acitretin; Baricitinib; Cyclosporine; Jak inhibitors; Methothrexate; Psoriasis; Psoriatic arthritis; Tofacitinib.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure Dr J. James has no conflicts of interest. Dr J. Gao received fellowship funding from Abbvie and Janssen. She is an investigator for Abbvie, Bristol Meyers Squibb, UCB, and Novartis. Dr T. Otto is an investigator for Abbvie, Bristol Meyers Squibb, UCB, and Novartis. Dr M.L. Porter is a consultant and/or an investigator for Abbvie, Bristol Meyers Squibb, Eli Lilly, Regeneron, Pfizer, UCB, Moonlake, Acelyrin, Incyte, Trifecta Clinical, and Novartis. She has previously received fellowship funding and honoraria from the National Psoriasis Foundation.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical